Accolade, Inc. - common stock (ACCD)
6.9500
0.00 (0.00%)
Accolade Inc is a technology-driven healthcare company that offers personalized health and benefits solutions
The company leverages data analytics and artificial intelligence to provide individuals and employers with tailored guidance in navigating complex healthcare systems. By pairing users with dedicated health assistants, Accolade aims to simplify healthcare decisions, enhance user experience, and improve health outcomes while helping organizations manage costs associated with employee health benefits. Through its innovative platform, the company optimizes access to care, navigates insurance options, and supports overall wellness initiatives.

Ark Invest made notable trades on Feb. 28, 2025. They purchased shares in ACHR, RXRX, TEM, and IRDM, while selling shares in TWST, ADYEY, ACCD, and EXAS.
Via Benzinga · March 1, 2025

Ark Invest made significant trades on Friday, including buying Amazon and Roblox stock and selling Palantir stock. Other key trades were also made.
Via Benzinga · February 8, 2025

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.
Via Benzinga · January 31, 2025

Accolade shares are trading higher on Wednesday after it announced that Transcarent will acquire the company.
Via Benzinga · January 8, 2025

On Wednesday January 22, 2025, Cathie Wood-led Ark Invest sold $927,107 worth of Robinhood shares.
Via Benzinga · January 22, 2025

Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI.
Via Benzinga · January 22, 2025

Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.
Via Benzinga · January 18, 2025

Via Benzinga · January 8, 2025

Via Benzinga · October 9, 2024

Via Benzinga · October 4, 2024

Transcarent to acquire Accolade Inc. for $7.03 per share, combining AI-driven care solutions with personalized healthcare expertise. Deal closes Q2 2025.
Via Benzinga · January 8, 2025

Accolade stock up after beating Q2 2025 revenue and EPS estimates, expecting full year Adjusted EBITDA profitability and positive cash flow.
Via Benzinga · October 8, 2024

Via Benzinga · October 8, 2024

Via Benzinga · October 8, 2024

Via Benzinga · October 4, 2024

Via Benzinga · June 28, 2024

Via Benzinga · June 28, 2024

Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!
Via InvestorPlace · June 28, 2024

ACCD stock results show that Accolade beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2025.
Via InvestorPlace · June 27, 2024

Accolade Inc shares are tanking in Thursday's after-hours session after the company reported financial results for its fiscal first quarter and issued weak guidance.
Via Benzinga · June 27, 2024

The popular growth investor bought into one of Thursday's biggest losers and two stocks that have fallen sharply over the past year.
Via The Motley Fool · May 10, 2024